5PSQ-136 Appropriateness of dapagliflozin prescription in heart failure

<h3>Background and Importance</h3> Heart failure (HF) is a leading cause of hospitalisation in Spain, associated with high morbidity in the adult population due to ageing demographics. Optimising available treatments is crucial to reduce hospitalisation risks and maximise early benefits. <h3>Aim and Objectives</h3> Evaluate the appropriateness of dapagliflozin prescription according to the funding and indications established in the technical data sheet of the product for HF in hospitalised patients, as well as to record the incidence of hospitalisations related to HF. <h3>Material and Methods</h3> A unicentric, observational, prospective study lasting 1 month (February - March 2024) was conducted to collect demographic (age and sex) and clinical variables (left ventricular ejection fraction (LVEF), NT-proBNP levels, date of prescription initiation and reason for admission), and pharmacotherapeutic history of hospitalised patients who were prescribed dapagliflozin in a tertiary care hospital. The study focused on patients who met the criteria for HF with LVEF &lt; 40% not controlled with first-line therapies (Angiotensin-converting enzyme (ACE) and angiotensin II receptor antagonists (ARA-II) combined with beta blockers) and second-line therapies (mineralocorticoid receptor antagonists (MRA)), as well as the treatment of symptomatic patients with LVEF &gt; 40% and elevated plasma NT-proBNP levels. Patients lacking sufficient variables for the study were excluded. Data collection was performed using program Farmatools and Excel. <h3>Results</h3> A total of 50 patients were analysed, 37 (73%) males, with a median age of 80 years (range 54–94). The primary services were: 20 patients (40%) Internal Medicine Department, 18 (36%) Cardiology, five (10%) Pulmonology, and seven (14%) others. 92% (46) of the patients met the indication criteria, the reasons for non-compliance were absence of symptoms in patients with LVEF &gt; 40% (two patients) and failure to use MRA in those with LVEF &lt; 40% (three patients). 76% (38) of the hospitalised patients had been previously prescribed dapagliflozin; among them, 39.5% (15) were hospitalised due to heart failure. <h3>Conclusion and Relevance</h3> A high percentage of them met the indication criteria. It would be advisable to evaluate the treatment strategy due to a notable percentage of hospital admissions for heart failure among patients with prior dapagliflozin prescriptions, which may compromise the drug’s benefits. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest